Expression and Clinical Significance of CREPT and CDK4 in Cervical Cancer
Abstract
No Abstract
1. Ramirez PT, Frumovitz M, Pareja R, et al (2018). Minimally invasive versus ab-dominal radical hysterectomy for cervical cancer. N Engl J Med, 379(20): 1895-1904.
2. Wang YM, Wang CJ, Fang FM, et al (2017). Differences in the outcomes and compli-cations between elderly and younger uter-ine cervical cancer patients treated by de-finitive radiotherapy - A propensity score-matched study. Gynecol Oncol, 145(2): 277-283.
3. Ma J, Ren Y, Zhang L, et al (2017). Knock-ing-down of CREPT prohibits the pro-gression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc ex-pression. PLoS One, 12(4): e0174309.
4. Zhang H, Han R, Ling ZQ, et al (2018). PAQR4 has a tumorigenic effect in hu-man breast cancers in association with reduced CDK4 degradation. Carcinogenesis, 39(3): 439-446.
5. Patel S, Pancholi P, Visal T, et al (2017). Ab-stract 2172: ON 123300, an orally admin-istered novel CDK4/6 + ARK5 inhibi-tor, exhibits potent antitumor activity in vivo: comparative studies with Palbo-ciclib. Cancer Res, 77: 2172.
6. Vijayaraghavan S, Karakas C, Doostan I, et al (2017). CDK4/6 and autophagy inhibi-tors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun, 8: 15916.
7. Bollard J, Miguela V, de Galarreta MR, et al (2017). Palbociclib (PD-0332991), a selec-tive CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepato-cellular carcinoma. Gut, 66(7): 1286-1296.
2. Wang YM, Wang CJ, Fang FM, et al (2017). Differences in the outcomes and compli-cations between elderly and younger uter-ine cervical cancer patients treated by de-finitive radiotherapy - A propensity score-matched study. Gynecol Oncol, 145(2): 277-283.
3. Ma J, Ren Y, Zhang L, et al (2017). Knock-ing-down of CREPT prohibits the pro-gression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc ex-pression. PLoS One, 12(4): e0174309.
4. Zhang H, Han R, Ling ZQ, et al (2018). PAQR4 has a tumorigenic effect in hu-man breast cancers in association with reduced CDK4 degradation. Carcinogenesis, 39(3): 439-446.
5. Patel S, Pancholi P, Visal T, et al (2017). Ab-stract 2172: ON 123300, an orally admin-istered novel CDK4/6 + ARK5 inhibi-tor, exhibits potent antitumor activity in vivo: comparative studies with Palbo-ciclib. Cancer Res, 77: 2172.
6. Vijayaraghavan S, Karakas C, Doostan I, et al (2017). CDK4/6 and autophagy inhibi-tors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun, 8: 15916.
7. Bollard J, Miguela V, de Galarreta MR, et al (2017). Palbociclib (PD-0332991), a selec-tive CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepato-cellular carcinoma. Gut, 66(7): 1286-1296.
| Files | ||
| Issue | Vol 50 No 2 (2021) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijph.v50i2.5365 | |
| PMCID | PMC7956077 | |
| PMID | 33748010 | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
YAO S, SUN H. Expression and Clinical Significance of CREPT and CDK4 in Cervical Cancer. Iran J Public Health. 2021;50(2):418-420.
